Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Not applicableNot Yet RecruitingNCT07687602
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

Who this might be right for
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian CancerFolate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube CancerFolate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
AbbVie 69
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Early research (Phase 1)Study completedNCT03552471
What this trial is testing

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationFolate Receptor Alpha Positive+7 more
Ohio State University Comprehensive Cancer Center 25
Large-scale testing (Phase 3)Study completedNCT02631876
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
ImmunoGen, Inc. 366